NEW YORK, NY / ACCESSWIRE / September 25, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Alteryx, Inc. (NYSE:AYX)
Class Period: May 6, 2020 - August 6, 2020
Lead Plaintiff Deadline: October 19, 2020
The AYX lawsuit alleges that Alteryx, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was unable to close large deals within the quarter, and deals were pushed out to subsequent quarters or downsized; (2) as a result, Alteryx increasingly relied on adoption licenses to attract new customers; (3) as a result and due to the nature of adoption licenses, the Company's revenue was reasonably likely to decline; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in AYX: http://www.kleinstocklaw.com/pslra-1/alteryx-inc-loss-submission-form?id=9627&from=1
Baidu, Inc. (NASDAQ:BIDU)
Class Period: April 8, 2016 - August 13, 2020
Lead Plaintiff Deadline: October 19, 2020
Throughout the class period, Baidu, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Baidu misrepresented the financial and business condition of iQIYI; (2) iQIYI had inadequate controls; and (3) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Learn about your recoverable losses in BIDU: http://www.kleinstocklaw.com/pslra-1/baidu-inc-loss-submission-form-2?id=9627&from=1
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: February 11, 2020 - August 10, 2020
Lead Plaintiff Deadline: November 2, 2020
Fennec Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in FENC: http://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?id=9627&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm